Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 12 entries
Sorted by: Best Match Show Resources per page
In vivo imaging reveals rapid astrocyte depletion and axon damage in a model of neuromyelitis optica-related pathology.

Annals of neurology

Herwerth M, Kalluri SR, Srivastava R, Kleele T, Kenet S, Illes Z, Merkler D, Bennett JL, Misgeld T, Hemmer B.
PMID: 26946517
Ann Neurol. 2016 May;79(5):794-805. doi: 10.1002/ana.24630. Epub 2016 Apr 18.

OBJECTIVE: Neuromyelitis optica (NMO) is an autoimmune disease of the central nervous system, which resembles multiple sclerosis (MS). NMO differs from MS, however, in the distribution and histology of neuroinflammatory lesions and shows a more aggressive clinical course. Moreover,...

Cite
Herwerth M, Kalluri SR, Srivastava R, et al. In vivo imaging reveals rapid astrocyte depletion and axon damage in a model of neuromyelitis optica-related pathology. Ann Neurol. 2016;79(5):794-805doi: 10.1002/ana.24630.
Herwerth, M., Kalluri, S. R., Srivastava, R., Kleele, T., Kenet, S., Illes, Z., Merkler, D., Bennett, J. L., Misgeld, T., & Hemmer, B. (2016). In vivo imaging reveals rapid astrocyte depletion and axon damage in a model of neuromyelitis optica-related pathology. Annals of neurology, 79(5), 794-805. https://doi.org/10.1002/ana.24630
Herwerth, Marina, et al. "In vivo imaging reveals rapid astrocyte depletion and axon damage in a model of neuromyelitis optica-related pathology." Annals of neurology vol. 79,5 (2016): 794-805. doi: https://doi.org/10.1002/ana.24630
Herwerth M, Kalluri SR, Srivastava R, Kleele T, Kenet S, Illes Z, Merkler D, Bennett JL, Misgeld T, Hemmer B. In vivo imaging reveals rapid astrocyte depletion and axon damage in a model of neuromyelitis optica-related pathology. Ann Neurol. 2016 May;79(5):794-805. doi: 10.1002/ana.24630. Epub 2016 Apr 18. PMID: 26946517; PMCID: PMC5021140.
Copy Download .nbib Format: NLM
Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN.

Therapeutic advances in neurological disorders

Newsome SD, Scott TF, Arnold DL, Nelles G, Hung S, Cui Y, Shang S, Naylor ML, Kremenchutzky M.
PMID: 30181778
Ther Adv Neurol Disord. 2018 Aug 28;11:1756286418791143. doi: 10.1177/1756286418791143. eCollection 2018.

BACKGROUND: ADVANCE was a phase III trial of the efficacy and safety of subcutaneous peginterferon beta-1a 125 µg every 2 or 4 weeks in patients with relapsing-remitting multiple sclerosis (RRMS). ATTAIN was a 2-year extension study of ADVANCE. The...

Cite
Newsome SD, Scott TF, Arnold DL, et al. Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN. Ther Adv Neurol Disord. 2018;11:1756286418791143doi: 10.1177/1756286418791143.
Newsome, S. D., Scott, T. F., Arnold, D. L., Nelles, G., Hung, S., Cui, Y., Shang, S., Naylor, M. L., & Kremenchutzky, M. (2018). Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN. Therapeutic advances in neurological disorders, 111756286418791143. https://doi.org/10.1177/1756286418791143
Newsome, Scott D, et al. "Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN." Therapeutic advances in neurological disorders vol. 11 (2018): 1756286418791143. doi: https://doi.org/10.1177/1756286418791143
Newsome SD, Scott TF, Arnold DL, Nelles G, Hung S, Cui Y, Shang S, Naylor ML, Kremenchutzky M. Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN. Ther Adv Neurol Disord. 2018 Aug 28;11:1756286418791143. doi: 10.1177/1756286418791143. eCollection 2018. PMID: 30181778; PMCID: PMC6113734.
Copy Download .nbib Format: NLM
Therapeutic Approaches to Insomnia and Fatigue in Patients with Multiple Sclerosis.

Nature and science of sleep

Drerup M, Roth A, Kane A, Sullivan AB.
PMID: 33623461
Nat Sci Sleep. 2021 Feb 16;13:201-207. doi: 10.2147/NSS.S256676. eCollection 2021.

The prevalence of sleep disorders in individuals with multiple sclerosis (MS) is 3-5 times higher compared to the general population. Insomnia Disorder, defined as difficulty falling asleep, maintaining sleep or waking up too early, can lead to significant fatigue,...

Cite
Drerup M, Roth A, Kane A, et al. Therapeutic Approaches to Insomnia and Fatigue in Patients with Multiple Sclerosis. Nat Sci Sleep. 2021;13:201-207doi: 10.2147/NSS.S256676.
Drerup, M., Roth, A., Kane, A., & Sullivan, A. B. (2021). Therapeutic Approaches to Insomnia and Fatigue in Patients with Multiple Sclerosis. Nature and science of sleep, 13201-207. https://doi.org/10.2147/NSS.S256676
Drerup, Michelle, et al. "Therapeutic Approaches to Insomnia and Fatigue in Patients with Multiple Sclerosis." Nature and science of sleep vol. 13 (2021): 201-207. doi: https://doi.org/10.2147/NSS.S256676
Drerup M, Roth A, Kane A, Sullivan AB. Therapeutic Approaches to Insomnia and Fatigue in Patients with Multiple Sclerosis. Nat Sci Sleep. 2021 Feb 16;13:201-207. doi: 10.2147/NSS.S256676. eCollection 2021. PMID: 33623461; PMCID: PMC7896778.
Copy Download .nbib Format: NLM
Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.

EBioMedicine

Gadani SP, Reyes-Mantilla M, Jank L, Harris S, Douglas M, Smith MD, Calabresi PA, Mowry EM, Fitzgerald KC, Bhargava P.
PMID: 34666226
EBioMedicine. 2021 Nov;73:103636. doi: 10.1016/j.ebiom.2021.103636. Epub 2021 Oct 16.

BACKGROUND: Sphingosine-1-phosphate receptor (S1P) modulators and anti-CD20 therapies impair humoral responses to SARS-CoV-2 mRNA vaccines. Relatively few studies have assessed the impact of an array of disease modifying therapies (DMTs) for multiple sclerosis (MS) on T cell immune responses...

Cite
Gadani SP, Reyes-Mantilla M, Jank L, et al. Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy. EBioMedicine. 2021;73:103636doi: 10.1016/j.ebiom.2021.103636.
Gadani, S. P., Reyes-Mantilla, M., Jank, L., Harris, S., Douglas, M., Smith, M. D., Calabresi, P. A., Mowry, E. M., Fitzgerald, K. C., & Bhargava, P. (2021). Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy. EBioMedicine, 73103636. https://doi.org/10.1016/j.ebiom.2021.103636
Gadani, Sachin P, et al. "Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy." EBioMedicine vol. 73 (2021): 103636. doi: https://doi.org/10.1016/j.ebiom.2021.103636
Gadani SP, Reyes-Mantilla M, Jank L, Harris S, Douglas M, Smith MD, Calabresi PA, Mowry EM, Fitzgerald KC, Bhargava P. Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy. EBioMedicine. 2021 Nov;73:103636. doi: 10.1016/j.ebiom.2021.103636. Epub 2021 Oct 16. PMID: 34666226; PMCID: PMC8520057.
Copy Download .nbib Format: NLM
Achieving effective patient and public involvement in international clinical trials in neurology.

Neurology. Clinical practice

Tallantyre EC, Evangelou N, Bale C, Chaudhry BZ, Gray EH, LaRocca N, Pavitt S, Miller DM, Planchon SM, Ontaneda D, Manzano A.
PMID: 32642328
Neurol Clin Pract. 2020 Jun;10(3):265-272. doi: 10.1212/CPJ.0000000000000739.

There is a growing need for patient and public involvement (PPI) to inform the way that research is developed and performed. International randomized controlled trials are particularly likely to benefit from PPI, but guidance is lacking on how or...

Cite
Tallantyre EC, Evangelou N, Bale C, et al. Achieving effective patient and public involvement in international clinical trials in neurology. Neurol Clin Pract. 2020;10(3):265-272doi: 10.1212/CPJ.0000000000000739.
Tallantyre, E. C., Evangelou, N., Bale, C., Chaudhry, B. Z., Gray, E. H., LaRocca, N., Pavitt, S., Miller, D. M., Planchon, S. M., Ontaneda, D., & Manzano, A. (2020). Achieving effective patient and public involvement in international clinical trials in neurology. Neurology. Clinical practice, 10(3), 265-272. https://doi.org/10.1212/CPJ.0000000000000739
Tallantyre, Emma C, et al. "Achieving effective patient and public involvement in international clinical trials in neurology." Neurology. Clinical practice vol. 10,3 (2020): 265-272. doi: https://doi.org/10.1212/CPJ.0000000000000739
Tallantyre EC, Evangelou N, Bale C, Chaudhry BZ, Gray EH, LaRocca N, Pavitt S, Miller DM, Planchon SM, Ontaneda D, Manzano A. Achieving effective patient and public involvement in international clinical trials in neurology. Neurol Clin Pract. 2020 Jun;10(3):265-272. doi: 10.1212/CPJ.0000000000000739. PMID: 32642328; PMCID: PMC7292561.
Copy Download .nbib Format: NLM
A Population-Based Investigation of Health-Care Needs and Preferences in American Adults With Multiple Sclerosis.

Journal of patient experience

Chiu C, Bishop M, McDaniels B, Kim BJ, Tiro L.
PMID: 32128369
J Patient Exp. 2020 Feb;7(1):34-41. doi: 10.1177/2374373518812078. Epub 2018 Nov 21.

BACKGROUND: Comprehensive and effective multiple sclerosis (MS) health care requires understanding of patients' needs, preferences, and priorities.OBJECTIVE: To evaluate priorities of patients with MS for their MS care.METHODS: Participants included 3003 Americans with MS recruited through the National MS...

Cite
Chiu C, Bishop M, McDaniels B, et al. A Population-Based Investigation of Health-Care Needs and Preferences in American Adults With Multiple Sclerosis. J Patient Exp. 2018;7(1):34-41doi: 10.1177/2374373518812078.
Chiu, C., Bishop, M., McDaniels, B., Kim, B. J., & Tiro, L. (2020). A Population-Based Investigation of Health-Care Needs and Preferences in American Adults With Multiple Sclerosis. Journal of patient experience, 7(1), 34-41. https://doi.org/10.1177/2374373518812078
Chiu, Chungyi, et al. "A Population-Based Investigation of Health-Care Needs and Preferences in American Adults With Multiple Sclerosis." Journal of patient experience vol. 7,1 (2020): 34-41. doi: https://doi.org/10.1177/2374373518812078
Chiu C, Bishop M, McDaniels B, Kim BJ, Tiro L. A Population-Based Investigation of Health-Care Needs and Preferences in American Adults With Multiple Sclerosis. J Patient Exp. 2020 Feb;7(1):34-41. doi: 10.1177/2374373518812078. Epub 2018 Nov 21. PMID: 32128369; PMCID: PMC7036688.
Copy Download .nbib Format: NLM
Multiple Sclerosis Functional Composite (MSFC): Scoring Instructions.

Noro psikiyatri arsivi

Tiftikçioğlu Bİ.
PMID: 30692855
Noro Psikiyatr Ars. 2018;55:S46-S48. doi: 10.29399/npa.23330.

It is important to assess the clinical outcome in patients with multiple sclerosis (MS) both during individual clinical follow-up and in clinical trials. The National MS Society's Clinical Outcomes Assessment Task Force has developed and recommended a multidimensional clinical...

Cite
Tiftikçioğlu Bİ. Multiple Sclerosis Functional Composite (MSFC): Scoring Instructions. Noro Psikiyatr Ars. 2018;55:S46-S48doi: 10.29399/npa.23330.
Tiftikçioğlu, B. �. �. (2018). Multiple Sclerosis Functional Composite (MSFC): Scoring Instructions. Noro psikiyatri arsivi, 55S46-S48. https://doi.org/10.29399/npa.23330
Tiftikçioğlu, Bedile İrem. "Multiple Sclerosis Functional Composite (MSFC): Scoring Instructions." Noro psikiyatri arsivi vol. 55 (2018): S46-S48. doi: https://doi.org/10.29399/npa.23330
Tiftikçioğlu Bİ. Multiple Sclerosis Functional Composite (MSFC): Scoring Instructions. Noro Psikiyatr Ars. 2018;55:S46-S48. doi: 10.29399/npa.23330. PMID: 30692855; PMCID: PMC6278631.
Copy Download .nbib Format: NLM
Corrigendum.

Multiple sclerosis (Houndmills, Basingstoke, England)

[No authors listed]
PMID: 28639535
Mult Scler. 2017 Nov;23(13):NP30. doi: 10.1177/1352458517717937. Epub 2017 Jun 22.

Cawley N, Tur C, Prados F, et al. Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis. Mult Scler. Epub ahead of print 18 May 2017. DOI: 10.1177/1352458517709954. On page 9 of...

Cite
Corrigendum. Mult Scler. 2017;23(13):NP30doi: 10.1177/1352458517717937.
(2017). Corrigendum. Multiple sclerosis (Houndmills, Basingstoke, England), 23(13), NP30. https://doi.org/10.1177/1352458517717937
"Corrigendum." Multiple sclerosis (Houndmills, Basingstoke, England) vol. 23,13 (2017): NP30. doi: https://doi.org/10.1177/1352458517717937
Corrigendum. Mult Scler. 2017 Nov;23(13):NP30. doi: 10.1177/1352458517717937. Epub 2017 Jun 22. PMID: 28639535.
Copy Download .nbib Format: NLM
Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.

Neurology

Simpson-Yap S, De Brouwer E, Kalincik T, Rijke N, Hillert JA, Walton C, Edan G, Moreau Y, Spelman T, Geys L, Parciak T, Gautrais C, Lazovski N, Pirmani A, Ardeshirdavanai A, Forsberg L, Glaser A, McBurney R, Schmidt H, Bergmann AB, Braune S, Stahmann A, Middleton R, Salter A, Fox RJ, van der Walt A, Butzkueven H, Alroughani R, Ozakbas S, Rojas JI, van der Mei I, Nag N, Ivanov R, Sciascia do Olival G, Dias AE, Magyari M, Brum D, Mendes MF, Alonso RN, Nicholas RS, Bauer J, Chertcoff AS, Zabalza A, Arrambide G, Fidao A, Comi G, Peeters L.
PMID: 34610987
Neurology. 2021 Nov 09;97(19):e1870-e1885. doi: 10.1212/WNL.0000000000012753. Epub 2021 Oct 05.

BACKGROUND AND OBJECTIVES: People with multiple sclerosis (MS) are a vulnerable group for severe coronavirus disease 2019 (COVID-19), particularly those taking immunosuppressive disease-modifying therapies (DMTs). We examined the characteristics of COVID-19 severity in an international sample of people with...

Cite
Simpson-Yap S, De Brouwer E, Kalincik T, et al. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. Neurology. 2021;97(19):e1870-e1885doi: 10.1212/WNL.0000000000012753.
Simpson-Yap, S., De Brouwer, E., Kalincik, T., Rijke, N., Hillert, J. A., Walton, C., Edan, G., Moreau, Y., Spelman, T., Geys, L., Parciak, T., Gautrais, C., Lazovski, N., Pirmani, A., Ardeshirdavanai, A., Forsberg, L., Glaser, A., McBurney, R., Schmidt, H., Bergmann, A. B., Braune, S., Stahmann, A., Middleton, R., Salter, A., Fox, R. J., van der Walt, A., Butzkueven, H., Alroughani, R., Ozakbas, S., Rojas, J. I., van der Mei, I., Nag, N., Ivanov, R., Sciascia do Olival, G., Dias, A. E., Magyari, M., Brum, D., Mendes, M. F., Alonso, R. N., Nicholas, R. S., Bauer, J., Chertcoff, A. S., Zabalza, A., Arrambide, G., Fidao, A., Comi, G., & Peeters, L. (2021). Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. Neurology, 97(19), e1870-e1885. https://doi.org/10.1212/WNL.0000000000012753
Simpson-Yap, Steve, et al. "Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis." Neurology vol. 97,19 (2021): e1870-e1885. doi: https://doi.org/10.1212/WNL.0000000000012753
Simpson-Yap S, De Brouwer E, Kalincik T, Rijke N, Hillert JA, Walton C, Edan G, Moreau Y, Spelman T, Geys L, Parciak T, Gautrais C, Lazovski N, Pirmani A, Ardeshirdavanai A, Forsberg L, Glaser A, McBurney R, Schmidt H, Bergmann AB, Braune S, Stahmann A, Middleton R, Salter A, Fox RJ, van der Walt A, Butzkueven H, Alroughani R, Ozakbas S, Rojas JI, van der Mei I, Nag N, Ivanov R, Sciascia do Olival G, Dias AE, Magyari M, Brum D, Mendes MF, Alonso RN, Nicholas RS, Bauer J, Chertcoff AS, Zabalza A, Arrambide G, Fidao A, Comi G, Peeters L. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. Neurology. 2021 Nov 09;97(19):e1870-e1885. doi: 10.1212/WNL.0000000000012753. Epub 2021 Oct 05. PMID: 34610987; PMCID: PMC8601210.
Copy Download .nbib Format: NLM
Is It Time for Quotas to Achieve Racial and Ethnic Representation in Multiple Sclerosis Trials?.

Frontiers in neurology

Mateen FJ.
PMID: 34054715
Front Neurol. 2021 May 13;12:680912. doi: 10.3389/fneur.2021.680912. eCollection 2021.

No abstract available.

Cite
Mateen FJ. Is It Time for Quotas to Achieve Racial and Ethnic Representation in Multiple Sclerosis Trials?. Front Neurol. 2021;12:680912doi: 10.3389/fneur.2021.680912.
Mateen, F. J. (2021). Is It Time for Quotas to Achieve Racial and Ethnic Representation in Multiple Sclerosis Trials?. Frontiers in neurology, 12680912. https://doi.org/10.3389/fneur.2021.680912
Mateen, Farrah J. "Is It Time for Quotas to Achieve Racial and Ethnic Representation in Multiple Sclerosis Trials?." Frontiers in neurology vol. 12 (2021): 680912. doi: https://doi.org/10.3389/fneur.2021.680912
Mateen FJ. Is It Time for Quotas to Achieve Racial and Ethnic Representation in Multiple Sclerosis Trials?. Front Neurol. 2021 May 13;12:680912. doi: 10.3389/fneur.2021.680912. eCollection 2021. PMID: 34054715; PMCID: PMC8155278.
Copy Download .nbib Format: NLM
Outcomes and future directions for neuroimmunology/multiple sclerosis fellowship training: Survey of recent trainees.

Multiple sclerosis and related disorders

Hua LH, Obeidat AZ, Longbrake EE.
PMID: 32585616
Mult Scler Relat Disord. 2020 Sep;44:102296. doi: 10.1016/j.msard.2020.102296. Epub 2020 Jun 10.

BACKGROUND: Neuroimmunology/multiple sclerosis is a rapidly evolving, but still poorly defined subspecialty. Fellowship training is not standardized, and there is substantial variability across sites. Outcomes of fellowship training have not yet been studied. We therefore examined early career choices...

Cite
Hua LH, Obeidat AZ, Longbrake EE. Outcomes and future directions for neuroimmunology/multiple sclerosis fellowship training: Survey of recent trainees. Mult Scler Relat Disord. 2020;44:102296doi: 10.1016/j.msard.2020.102296.
Hua, L. H., Obeidat, A. Z., & Longbrake, E. E. (2020). Outcomes and future directions for neuroimmunology/multiple sclerosis fellowship training: Survey of recent trainees. Multiple sclerosis and related disorders, 44102296. https://doi.org/10.1016/j.msard.2020.102296
Hua, Le H, et al. "Outcomes and future directions for neuroimmunology/multiple sclerosis fellowship training: Survey of recent trainees." Multiple sclerosis and related disorders vol. 44 (2020): 102296. doi: https://doi.org/10.1016/j.msard.2020.102296
Hua LH, Obeidat AZ, Longbrake EE. Outcomes and future directions for neuroimmunology/multiple sclerosis fellowship training: Survey of recent trainees. Mult Scler Relat Disord. 2020 Sep;44:102296. doi: 10.1016/j.msard.2020.102296. Epub 2020 Jun 10. PMID: 32585616; PMCID: PMC8023409.
Copy Download .nbib Format: NLM
Alterations of the gut mycobiome in patients with MS.

EBioMedicine

Shah S, Locca A, Dorsett Y, Cantoni C, Ghezzi L, Lin Q, Bokoliya S, Panier H, Suther C, Gormley M, Liu Y, Evans E, Mikesell R, Obert K, Salter A, Cross AH, Tarr PI, Lovett-Racke A, Piccio L, Zhou Y.
PMID: 34455391
EBioMedicine. 2021 Sep;71:103557. doi: 10.1016/j.ebiom.2021.103557. Epub 2021 Aug 26.

BACKGROUND: The mycobiome is the fungal component of the gut microbiome and is implicated in several autoimmune diseases. However, its role in MS has not been studied.METHODS: In this case-control observational study, we performed ITS sequencing and characterised the...

Cite
Shah S, Locca A, Dorsett Y, et al. Alterations of the gut mycobiome in patients with MS. EBioMedicine. 2021;71:103557doi: 10.1016/j.ebiom.2021.103557.
Shah, S., Locca, A., Dorsett, Y., Cantoni, C., Ghezzi, L., Lin, Q., Bokoliya, S., Panier, H., Suther, C., Gormley, M., Liu, Y., Evans, E., Mikesell, R., Obert, K., Salter, A., Cross, A. H., Tarr, P. I., Lovett-Racke, A., Piccio, L., & Zhou, Y. (2021). Alterations of the gut mycobiome in patients with MS. EBioMedicine, 71103557. https://doi.org/10.1016/j.ebiom.2021.103557
Shah, Saumya, et al. "Alterations of the gut mycobiome in patients with MS." EBioMedicine vol. 71 (2021): 103557. doi: https://doi.org/10.1016/j.ebiom.2021.103557
Shah S, Locca A, Dorsett Y, Cantoni C, Ghezzi L, Lin Q, Bokoliya S, Panier H, Suther C, Gormley M, Liu Y, Evans E, Mikesell R, Obert K, Salter A, Cross AH, Tarr PI, Lovett-Racke A, Piccio L, Zhou Y. Alterations of the gut mycobiome in patients with MS. EBioMedicine. 2021 Sep;71:103557. doi: 10.1016/j.ebiom.2021.103557. Epub 2021 Aug 26. PMID: 34455391; PMCID: PMC8399064.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 12 entries